Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can someone link to comella's response video to FDA warning?
The CEO
Worked at Worldcom. You should go look that up and see how it Ended if you own this stock
Sad to see Murphy buying
I miss You Chico
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
http://www.nejm.org/doi/full/10.1056/NEJMc1708349#t=article
Is Marijuana’s “Entourage Effect” Scientifically Valid?
https://www.scientificamerican.com/article/some-of-the-parts-is-marijuana-rsquo-s-ldquo-entourage-effect-rdquo-scientifically-valid/
I saw someone bragging in a SeekingAlpha comments section about GW and the 'entourage effect'.
Let me tell you that is very Fake news! Believe me.
Also some interesting comments about Syndros and Sativex.
I like Where I am at on the racetrack
Are you one of those Ban the Fed guys?
I'm not a macro guy. But 20 million is still 20 million. NMUS has been spending about a one million on research and licenses, so 20 would go a long way. [t][/t]
With that 20m, they could do different things. All of those involve one of their candidates completing a Phase 2 trial in 2018.
Before Zynerba's readouts, the Street was giving them a 250m market cap with 60ish million cash. Imagine what they would of been valued at with Positive results!
I don't know where along the development path Nemus will find a partner for one of their indications, if at all. However, the further Nemus goes down the road of approval with a drug(s), the market will price in a % of potential revenues from the drug(s). If required, I think future financings will be done at a higher valuation and be less dilutive than in the past than the most recent one.
If the most recent financing was to fall though and not complete, I think NMUS will be able to raise capital to continue operations and research. Since the company has completed previous raises diligently, and I would assume do the same in the future. One of the many advantages of owning shares in a company run by Good operators. 5-10m gets them into Phase 2 with something IMO.
Even though People got burned with ZYNE, the interest is there for the space and the Scoreboard won't lie.
You are right that ElSohly and UM were involved with another pharma about something that sounds similar to NB1222 and it didn't go through. I remember an article was posted awhile back. I don't think enough information is available to be able to form a strong opinion about why things never moved forward. It was a long time ago too. Post anything you have about it.
How can you say that there is no data showing the improved pharmacokinetics of the THC-VHS prodrug (NB1222)?
http://www.sciencedirect.com/science/article/pii/009130579390194X
http://europepmc.org/abstract/med/8897084
There is some on the NMUS website too.
The current patent is here: https://www.google.com/patents/US8809261
I'm not sure what the formulation would be with a transmucosal patch. I guess it would depend on what indication it is. But seems like down the list of things considering NB1222 (suppository) and NB1111 (eye drops-->contact lense)
'wouldn't the absorption as a suppository be too quick?' No, see the above research. I think NMUS is in the proccess of answering your question. NMUS will prove it on the field anyway. You can say whatever you want, but the scoreboard doesn't lie.
You ask tough questions CJ
I have always enjoyed that, you have made me Sharper
the 'downtrend'
However, what they do realize is a lot of dumb money does use this newest nitch charting or TA (Technical Analysis) to run a stock either up or down. To the MMs this is like taking candy from a baby. Simply they will paint the tape and use whatever tactic to affect the charting bands. Thus the public and dumb money they will have eating out of their hands. Effectively the MMs can show a strong stock growing weak by manipulating the close price in order to generate selling volume, delaying trading time to manipulate trading activities, or even stalling the ask without honoring orders to hold a stock price.
Confessions of an OTC MM
https://www.reddit.com/r/weedstocks/comments/1xydch/market_maker_speaks_out_ways_of_a_market_maker/
Reading charts is beyond my paygrade
GLTFA
the Series C guys
have fully converted, no? Maybe they are selling, 100k block today at .253....
Were at 40M fully diluted
and if the financing goes through (Series D) it will mean another 60m shares of common stock if fully converted.
So, not triple. And while that is significant dilution, the EV of the company doesn't change immediately (market cap - cash) and given the position Nemus has worked to get itself in, that Cash will be used to show the efficacy of Two of their drugs in clinical trials. These trials will go Well because Nemus has done their homework.
If your a Long, that means a significant re-rate of the stock price (which is a metric for how much the market values the pipeline) Even with the dilution.
Look at Zynerba, swing and a Miss on their lead candidate but Market Cap - Cash still values the Pipeline at around 20m. That is with a candidate apparently entering Phase 3 after failing Phase 2 trials, and a pre-clinical drug.
I think the score will be much different in a year.
PS = even with the Series D financing, Nemus will have = or less shares outstanding than $CNBX $IMLFF $OWCP which all have bigger market caps than Nemus right now. They have done all their financing's diligently thus far.
They will never do this
If something is PR worthy, they will announce. Like the NB2 data a few weeks ago
PR to fluff The PPS is minor League stuff. Look elsewhere if that is your thing
day to Day is just a Mark
i like where I am sitting on the Racetrack
The last post
Money well spent
'At InMed, Dr. Ado Muhammed, MD, DPM and MFPM, is the chief medical officer. He previously served as associate medical director at GW Pharmaceuticals, where he was key in leading the company in the development and FDA approval of one of the first cannabis drugs. InMed is the only cannabis biotech company led by a former GW Pharmaceuticals executive. '
How many times are they going to say this? What did he do there?
Looks like a Lot of progress is being made
In the N/A sector
the advantages
of owning shares of a company
that is not a scam or run by bad operators
You should know about Bogart
and Schendier
They have about 12m shares
And now are both no longer with the company in any official role
gltfa
10Q
Re Schneider financing
"In connection with the signing of the securities purchase agreement, an affiliate of the purchaser entered into a financial guarantee to the benefit of the Company that provides for payment of the purchase price in full within 90 days of exercise. The Company exercised this guarantee on July 12, 2017."
Yikes. Hope these guys get it together and can pay the 20m.
I remember when I called schneider and asked about what was going on. The guy said 'we still want to do the deal, but we Can't speak for Nemus'. Murphy and Co seemed Pissed off.
I hope management takes their anger out on a NDA submission via 505b2 for NB1222 targeted CINV.
Will need to raise capital first though.
Stock decline is due to
bogart resigning as IR or ZYNE CBD gel failing and investors worrying about INMeds gel for EB?
When did I say cannabinoids are a cure all CJ?
Large body of evidence shows cannabis has a variety of therapeutic effects --> those therapeutic effects likely originate from only a few of the 100's of compounds in the plant --> the best way to take advantage of the therapeutic effects of cannabis is to synthetically create and improve the most efficacious compounds for the given indication /thread
Nemus gave Schneider 90 days extension to pay up. 60 days left.
NB2 is a CBD analogue
'A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests.'
So maybe that will avoid Any patent infringement issues
NB2111 patent concerns with GW being low energy
It would appear GW is being very Rude about protecting Epidiolex -->
https://hoban.law/blog/2017/2017-02/gw-pharmaceuticals-shot-across-bow-americas-hemp-and-cbd-industries
Thoughts on how this could effect NB2?
Also, did anyone see how GW has delayed completed their NDA for Epidiolex because of construction at a new extraction facility? If only there was a quicker and cheaper way To manufacture....
https://seekingalpha.com/article/4096071-gw-pharmaceuticals-gwph-ceo-justin-gover-q3-2017-results-earnings-call-transcript?part=single
Also, no mention of Sativex during the call. Swing and a Miss
Yes, I understand that
But part of the thesis of cannabinoid drug development is that A. you already know the compounds are efficacious & B. there is already an established safety profile.
I found out that in the ZYN002 trials for PTSD, that patients were not wash the application site of the cream for 12 Hours.
http://zynerba.com/wp-content/uploads/2016/10/ZYN-002-MHSRS-poster-8-9-16v5-1-1.pdf
Someone on Twitter wondered that maybe in the latest trials Zynerba weren't as stringent about the application site post-admin, or weren't allowed to be, compared to their pre-clinical research.
Anyways, congrats to anyone Who caught the ZYNE knife and is riding the wave!
Back when I was making up my mind
how to play Vinpat's thesis, i thought about buying 50/50 NMUS/ZYNE, or all ZYNE and no NMUS.
That was when ZYNE was trading around 20
I don't think it matters whether they succeed or fail with their targets, so I'd rather see them succeed.
I just don't get how something like this would happen. Did they discuss the chance of missing Every metric?
Almost shocking
Listen to this Vinpat guy
Im very lucky to have found him
And to call him a friend
gltfa
Dyodd
to those who got hurt by $ZYNE today, I wrote about them and the therapeutic effects of cannabis https://theroadufollowed.wordpress.com/ $NMUS $GWPH
THe market could stay irrational
longer than You can stay sane LOL
Good news though; the last PR has been labelled property (NB2111) so we don't have to be confused about this one.
Here is the agenda for the conference: https://cpdaconference.org/wp-content/uploads/2016/05/2017-CONFERENCE-AGENDA-draft-07_28_2017.pdf
If Chico was wondering if it was Fake News
I guess we shouldn't worry about the Financing if they are finding time to present NB2111 research to peers
CANT sure wants to get filled at .253 it seems...
'Plant derived drugs aren't uncommon or inferior.
The advantage with biosynthesis is mainly reduced time and cost.'
If one route of manufacturing produces a higher volume with less costs, how is the other method not inferior? I know it is not uncommon, but wouldn't cannabis variability make it more difficult than your average plant? The more variable the species = the more synthetics make the better route? Why are you even bothering Growing it considering the risks and GMP costs....
Targeted synthetics outperform the plant 10/10 times for that specific indication. Even if some of the 550ish compounds have a net positive effect, clearly it is not big enough to warrant smoking/edibles over a synthetic. And if they do have a benefit, that will be discovered and drugs improved one day.
Are cannabinoids via IV the best? The study I referenced would indicate not.....
'hough I'm skeptical that NB1111 will be successful because of tolerance'
Tolerance to what? The latest research said 1%< THC?
'"But if it's valued at a couple hundred million $$ then that's not bad for a few years work...".
Not bad at all, is that just a hypothetical figure or what you actually think it could be worth to Nemus? '
If the CINV market is 2b, and they can get 5% of that for a sustained period, you can do the math
i got 50m from this website
https://www.pharmacompass.com/prescriptions/dronabinol but it does say 'drug cost' and not 'drug sales'.
the PR firm said this:
'Thank you for pointing out the discrepancy in the molecule identifiers. To clarify, Nemus is developing a prodrug of THC and an analogue of CBD.
The NB1XXX series refers to the prodrug of THC based candidates: NB1111 for glaucoma and NB1222 for CINV.
The NB2XXX series refers to the analogue of CBD based candidates: NB2111 for CIPN/pain and NB2222 for ocular conditions.
There is a table on the current company website that delineates the pipeline molecules as well as the projected market size for the target conditions.
We apologize for the confusion and the company will correct the press release on its website.'
I read that Valeants Marinol gets around 80% of the CINV market in Canada...
And isn't Dronabinol sales in US +50m?
I think your right about the NB1222/NB2222 mixup. Both CBD analogues, but NB2222 is for ocular targets. Someone should e-mail PR
Nemus has completed pre-IND meetings.
I tried to avoid any speculative statements.
I references the 505(b)(2) pathway and readers can make up their own mind in regards to what it means for the value of the company.
Updates in the fall on candidates would be great and I reference the data just presented on NB1111. But There is less data available from the UM about MRSA/CIPN, so I didn't want to get into much detail.
It was supposed to be All stuff no Fluff
Chico Marico Despacito
Vinpat, I stayed up all night
So I could Give this you before the Weekend
you Inspired me to write this
https://theroadufollowed.wordpress.com/
and then THIS GUY from Seeking Alpha MOTIVATED ME TO FINISH IT = https://seekingalpha.com/article/4085578-political-risk-increases-medical-marijuana
the greatest motivator in Life is disrespect
I probably won't do Another one of these
but Chico, I am warning you, I AM NOT RUNNING ON FUMES
I have plenty more to say about Nemus if you mouth off
GLTFA AND DYODD
if you need liquidity
etrade will help you with 50k bid @ $.26
or Cantor with 200k bid @ $.25
Do they think were Stupid?
good things come to those who wait
and I have something I've been working Hard on the last few weeks
if you Liked my comparison of NMUS and IMLFF I think you will like it
I made it for Vinpat
I hope he will enjoy
Don't let go of the Rope.Its hard to get Beat when you don't give up
does $INSY syndros bypass the first pass effect?
I agree that they shouldn't be
wasting their time with litigation.
With the some of the old Warrants and preferreds @ .25c I don't think its that surprising we have been chopping between .25-30 since the deal was 'delayed'
dyodd
All their synthetics
Have no patents or patents pending. Where they are pending I don't know
I am Pretty sure the 'Phase 2' study was Just oral CBD that wouldn't bypass the liver.
David Stefansky and All the people involved in the .05 CAD private placement right before the RTO did a real Good number on this one
Good Luck to them though
i don't think what I brought to light was enough
NMUS has good lawyers and they will bury You alive if you Mess up
i think that Schneider is a private company and limited information is available. because were only getting 1/10 of the picture, we shouldn't have formed our entire opinion. an example of this is Schneider Finance LLC in Nevada being listed as inactive on corportationwiki.com but if you search the Nevade State website it is active and up to date.
LP's are raising stupid amounts of money in Canada. if the Deal was not to close I wouldn't be worried about them raising 1-2m to 'keep the lights on' and for R&D burn. The risk becomes in 12 months the original deal UM expires, and Nemus will Have to pay up to continue.
But by then, I think things will be much different. I think Nmus goes deep Q1 and 2 2018. Some of you Know what the means. Upper Deck Moon Shot.
hope all is well Vinpat
GLTFA
'The .25's are trickling out'
Sounds very fake news.
You can get insider holdings info from SEC filings....i dont see noteworthy changes
Risking the erosion of 90% of your capital, to sell at a 5-10% gain (before fees and expenses) doesn't sound Smart.
Someone told me Schneider got a 90 day extension for the deal. I think they are Raising money externally too, not just from the inside.
NEMUS needs cash soon, but if The deal doesn't close I am sure they can raise 1-2m to push into 2018.
Will get Very ugly for Schneider if the deal doesn't close. Nemus has expensive and serious Lawyers.
what else did you find about schneider
?